HER2 Support Group Forums - View Single Post - a drug already approved found to make chemotherapy more effectve&protects normalcells

Lani · 05-21-2006, 09:07 AM

even though it is an MRI contrast agent it is a very specialized contrast agent for looking a liver lesions . Here is a paper describing the usefulness of the agent in determining if liver lesions are resectable (another practical use of this agent in her2neu patients?) After "googling" I found the compound's molecular size and will try to look up if this means it can cross the blood-brain barrier:

Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability

Gary N. Mann, MD, Howard F. Marx, MD, Lily L. Lai, MD and Lawrence D. Wagman, MD
From the Department of General Oncologic Surgery (GNM, LLL, LDW) and Division of Radiology (HFM), City of Hope National Medical Center, Duarte, CA 91010.

Correspondence: Address correspondence and reprint requests to: Gary N. Mann, MD, Department of Surgery, Section of Surgical Oncology, University of Washington, 1959 NE Pacific Street, P.O. Box 356410, Seattle, WA 98195; Fax: 206-543-8136; E-mail: gnmann@ u.washington.edu.

Background: Improved preoperative assessment of focal liver disease and tumors could have a potentially significant impact on their treatment. Mangafodipir trisodium (Teslascan; Nycomed Amersham Imaging, Little Chalfont, UK) is a new hepatocellular contrast agent for use with state-of-the-art MR imaging that, in early reports, is accurate in detection and characterization of liver lesions.

Methods: Records and diagnostic images of all patients undergoing enhanced Teslascan MRI (T-MRI) at our institution were reviewed. We assessed the relative sensitivities of contrast-enhanced CT scan (CECT) and T-MRI in detecting lesions, as well as the impact of T-MRI in the decision to operate or not on patients. In those patients taken to surgery, the correlation between T-MRI and intraoperative palpation and intraoperative ultrasound (IOUS) was determined.

Results: Fifty-four patients were noted on CECT to have focal liver lesions and subsequently underwent imaging with T-MRI. The T-MRI correlated with CT findings in 22 patients (41%), upstaged the liver disease in 26, and demonstrated fewer lesions in 6. Only 43 patients were considered operative candidates and T-MRI influenced the operative decision in 32 patients (74%), dissuading operative intervention in 14. In the 25 patients without clear preoperative evidence of unresectability who were taken to the operating room, T-MRI correlated with findings of intraoperative palpation in 19 (76%). In the 20 patients who underwent IOUS, T-MRI correlated with IOUS in 14 patients (70%). IOUS detected an additional nine lesions, all of which were <1 cm. Seventeen patients underwent resection and/or ablation of their liver lesions. Compared with pathology, sensitivities of CECT, T-MRI, and intraoperative evaluation were 61%, 83%, and 93%, respectively. T-MRI failed to predict hepatic-specific unresectability in only one of eight patients, the other seven having extrahepatic disease.

Conclusions: These findings suggest that T-MRI is more sensitive than CECT in the preoperative predicting of the resectability of hepatic lesions. Despite T-MRI accurately correlating with intraoperative surgical findings, IOUS should be performed on all patients prior to a final decision to resect or ablate a focal liver lesion.

05-21-2006, 09:07 AM	#2
Lani Senior Member Join Date: Mar 2006 Posts: 4,783	more info-- even though it is an MRI contrast agent it is a very specialized contrast agent for looking a liver lesions . Here is a paper describing the usefulness of the agent in determining if liver lesions are resectable (another practical use of this agent in her2neu patients?) After "googling" I found the compound's molecular size and will try to look up if this means it can cross the blood-brain barrier: Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability Gary N. Mann, MD, Howard F. Marx, MD, Lily L. Lai, MD and Lawrence D. Wagman, MD From the Department of General Oncologic Surgery (GNM, LLL, LDW) and Division of Radiology (HFM), City of Hope National Medical Center, Duarte, CA 91010. Correspondence: Address correspondence and reprint requests to: Gary N. Mann, MD, Department of Surgery, Section of Surgical Oncology, University of Washington, 1959 NE Pacific Street, P.O. Box 356410, Seattle, WA 98195; Fax: 206-543-8136; E-mail: gnmann@ u.washington.edu. Background: Improved preoperative assessment of focal liver disease and tumors could have a potentially significant impact on their treatment. Mangafodipir trisodium (Teslascan; Nycomed Amersham Imaging, Little Chalfont, UK) is a new hepatocellular contrast agent for use with state-of-the-art MR imaging that, in early reports, is accurate in detection and characterization of liver lesions. Methods: Records and diagnostic images of all patients undergoing enhanced Teslascan MRI (T-MRI) at our institution were reviewed. We assessed the relative sensitivities of contrast-enhanced CT scan (CECT) and T-MRI in detecting lesions, as well as the impact of T-MRI in the decision to operate or not on patients. In those patients taken to surgery, the correlation between T-MRI and intraoperative palpation and intraoperative ultrasound (IOUS) was determined. Results: Fifty-four patients were noted on CECT to have focal liver lesions and subsequently underwent imaging with T-MRI. The T-MRI correlated with CT findings in 22 patients (41%), upstaged the liver disease in 26, and demonstrated fewer lesions in 6. Only 43 patients were considered operative candidates and T-MRI influenced the operative decision in 32 patients (74%), dissuading operative intervention in 14. In the 25 patients without clear preoperative evidence of unresectability who were taken to the operating room, T-MRI correlated with findings of intraoperative palpation in 19 (76%). In the 20 patients who underwent IOUS, T-MRI correlated with IOUS in 14 patients (70%). IOUS detected an additional nine lesions, all of which were <1 cm. Seventeen patients underwent resection and/or ablation of their liver lesions. Compared with pathology, sensitivities of CECT, T-MRI, and intraoperative evaluation were 61%, 83%, and 93%, respectively. T-MRI failed to predict hepatic-specific unresectability in only one of eight patients, the other seven having extrahepatic disease. Conclusions: These findings suggest that T-MRI is more sensitive than CECT in the preoperative predicting of the resectability of hepatic lesions. Despite T-MRI accurately correlating with intraoperative surgical findings, IOUS should be performed on all patients prior to a final decision to resect or ablate a focal liver lesion.